Drug intelligence / Profile preview

S-(2-boronoethyl)-L-cysteine hydrochloride

Development stage
Preclinical
Modality
Small Molecules
Administration
In Vitro, In Vivo (animal Experiment), No Known Human Therapeutic Administration Route
01

Overview

**S-(2-boronoethyl)-L-cysteine hydrochloride (BEC hydrochloride)** is a boronic acid-based arginine analog and a potent, slow-binding, competitive inhibitor of **arginase I and arginase II**. Its mechanism involves binding to the active site of arginase enzymes, thereby preventing arginine hydrolysis. Reported **Ki** values are 0.4–0.6 μM against recombinant rat arginase I and 0.31 μM (pH 7.5) for human arginase II. BEC hydrochloride is used in biochemical research to investigate the role of arginase in nitric oxide production, endothelial function, inflammation, and cell proliferation, particularly in models of smooth muscle relaxation, pulmonary hypertension, and vascular inflammation. It does not act on inducible nitric oxide synthase at relevant concentrations[2][3][5][6][7].

Other names
(S)-(2-boronoethyl)-L-cysteineHCl(R)-2-amino-3-((2-boronoethyl)thio)propanoic acid hydrochlorideMethsuximide Impurity 1
02

Targets

ARG2 (Arginase 2)ARG1 (Arginase 1)

Beyond the preview

Go deeper on S-(2-boronoethyl)-L-cysteine hydrochloride.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on S-(2-boronoethyl)-L-cysteine hydrochloride.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call